EUCTR2012-002640-25-GB进行中（未招募）1 期
A prospective, single-centre, feasibility study evaluating the prevalence of diagnostic clinical imaging features of subclinical enthesitis in patients with moderate to severe plaque psoriasis and the response to skin directed treatment with Ustekinumab - MUSTEK Study (Protocol Version 1.0)
niversity of Leeds/Leeds Teaching Hospitals NHS Trust0 个研究点目标入组 30 人开始时间: 2013年1月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male and female patients aged from 18 to 80 years (inclusive) 2. A clinical diagnosis of chronic plaque psoriasis 3. Duration of psoriasis greater than twelve months 4. Moderate or severe skin disease (classified as a PASI score >10) 5. No prior treatment with systemic or biologic agents 6. No current or prior symptoms of psoriatic arthritis (or arthralgia/articular symptoms) 7. A physical ability to undergo USS, OCT and MRI scanning 8. An ability to permit the administration of subcutaneous medication by Dr Laura Savage (PI). 9. All male and female subjects biologically capable of having children must agree to use at least one reliable method of contraception for the duration of the study and for 24 weeks after the end of the study. Acceptable methods of contraception are surgical sterilization, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1. Male and female patients aged 17 and under or 81 and over (inclusive) 2. Psoriasis of mild to moderate psoriasis (PASI<10) 3. Previous treatment with any systemic or biologic agents (for psoriasis or any other indication) 4. Patients unable or not willing to attend all imaging, serological and clinical assessments 5. Any contraindication to MRI scanning (e.g. pacemaker, aneurysm coil) 6. Patients not willing to use adequate contraceptive methods 7. Pregnancy or breast feeding 8. Any contraindication to biologic therapy: o Active infection, including open leg ulcers, HIV, hepatitis B or C carriers o Active or latent tuberculosis o Malignancy – current, or previous within the last ten years (except basal cell carcinoma) o Severe heart failure (NYHA grade 3 or more) o Demyelinating disorders o Uncontrolled diabetes o Chronic lung disease (pulmonary fibrosis or bronchiectasis) o Previous PUVA phototherapy (>1000 joules) 9. History of other significant medical conditions, including: o Severe pulmonary disease (defined as requiring previous hospital admission or supplemental oxygen) o Active or severe cardiovascular disorders: uncontrolled hypertension, myocardial infarction within the previous twelve months, unstable angina within the previous six months) o Any immunodeficiency disorder o Connective tissue diseases (e.g. primary Sjogrens syndrome, systemic sclerosis, systemic lupus erythematosus, polymyositis) o Renal impairment (creatinine clearance <45ml/min) o Abnormal liver function tests (alanine transferase >3x upper limit of normal) o Blood disorders, i.e. neutropenia (neutrophils <2.0x109/l), thrombocytopenia (platelets <125x109/l) or anaemia (haemoglobin <8g/dl). 10. Any forthcoming event that may interrupt participation (e.g. a holiday, elective hospital admission) lasting longer than 14 days. Whilst some of the above are absolute contraindications, physician discretion will be applied as in usual clinical practice.
研究者
相似试验
招募中
不适用
An explorative, single-center, feasibility study to collect data for the continuous development of the TENA Bladder Sensor Algorithm in adults during urodynamics.Involuntary leakage of urineUrgency10046590NL-OMON51822Essity Hygiene and Health AB66
招募中
不适用
Prospective, single-centre, feasibility study to evaluate the use of 18F-PSMA PET/CT in patients with biochemically active medullary thyroid cancer.Medullary thyroid cancer10043739thyroid cancerNL-OMON51749niversitair Medisch Centrum Groningen15
Unknown
不适用
Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer ScreeningBreast Cancer ScreeningNCT04102722Transonic Imaging, Inc.1,333
已完成
不适用
Oral glucose tolerance test in first trimester of pregnancyGestational diabetesNutritional, Metabolic, EndocrineISRCTN18906333Southend Hospital NHS Foundation Trust50
已完成
不适用
A Single-center, Feasibility Study to Evaluate the Use and Safety of the Percutaneous Ultrasound Gastrostomy TechniqueGastrostomyNCT03575754CoapTech25